

# Depths of Malignancy: On the Prognosis of Breast Cancer [Response to Letter]

Jing He<sup>1,\*</sup>, Ling Tong<sup>2,\*</sup>, Ping Wu<sup>3</sup>, Yibo Wu<sup>2</sup>, Weifeng Shi<sup>1</sup>, Ling Chen<sup>1</sup>

<sup>1</sup>Department of Breast Surgery, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, People's Republic of China; <sup>2</sup>Human Reproductive Medicine Center, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, People's Republic of China; <sup>3</sup>Department of Clinical Nutrition, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, People's Republic of China

\*These authors contributed equally to this work

Correspondence: Ling Chen; Weifeng Shi, Email rainbow\_lyn@163.com; 576095187@qq.com

## Dear editor

We are honored that our published article has been read and paid attention by many people. In the following, I will explain one by one according to the reader's questions.

Firstly, none of the patients were lactating women. Secondly, as mentioned in the article, this study was only a single-center study, and the sample size (134 cases) may not be sufficient to fully reflect the status of breast cancer patients. Meanwhile, it is short of follow-up time and lacks OS. Median follow-up time was 45 months and most postoperative breast cancer patients often confront the first peak time of recurrence before 36 months.<sup>1</sup> Due to the credible and complete quantitative data on PFS, the value of LAR for the prognosis of breast cancer patients is compelling and sufficient, especially for those who may suffer the first recurrent peak. Thirdly, C-reactive protein is a vital inflammatory marker and I think it would be a good research direction. Finally, lymphatic fluid is less accessible than blood, so we selected blood as a medium.

## Disclosure

The authors report no conflicts of interest in this communication.

## Reference

1. Ribelles N, Perez-Villa L, Jerez JM, et al. Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. *Breast Cancer Res.* 2013;15(5):R98. doi:10.1186/bcr3559

Dove Medical Press encourages responsible, free and frank academic debate. The content of the International Journal of General Medicine 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the International Journal of General Medicine editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

International Journal of General Medicine

Dovepress

## Publish your work in this journal

The International Journal of General Medicine is an international, peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-general-medicine-journal>

<https://doi.org/10.2147/IJGM.S415713>

International Journal of General Medicine 2023:16 1807

1807

Received: 4 April 2023  
Accepted: 6 April 2023  
Published: 15 May 2023



© 2023 He et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <https://www.dovepress.com/terms.php> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<http://creativecommons.org/licenses/by-nc/3.0/>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<https://www.dovepress.com/terms.php>).